United States

A snapshot of PrEP scale-up, registration and resources for the United States.

  • 130,000-135,000
    Estimated Number of Current PrEP Users

    Aggregates numbers reported from demonstration projects, PEPFAR dashboard and program/country reports where available. This is presented as a range due to difficulty in tracking precise numbers and possible double reporting.

Data Updated: October 15, 2019

Drug Registration Status

  • Gilead's Truvada (TDF/FTC) registration
    Approved
  • Generic versions of TDF/FTC for prevention
    Not submitted

Types of Delivery Projects

  • Clinical trials
  • Demonstration projects — which road-test the use of new options in real-world settings—not in a trial site. They have a formal evaluation component that is designed to address specific elements of introduction such as infrastructure needs and ways individuals can integrate it into daily activities
  • Large-scale implementation initiative — funded/implementer involvement and investment in some or all steps related to comprehensive introduction that may or may not use government clinics as the primary service delivery point – e.g., Kenya’s Jilinde program
  • National level — PrEP availability in government clinics

Research, Demonstration and Implementation Projects

Policy Framework

Funding

  • NICHD
  • California HIV/AIDS Research Program
  • California Collaborative Treatment Group
  • CDC Foundation
  • NIAAA
  • Public Health Foundation Enterprises, Inc.
  • UCLA

Eligibility Criteria

Recommended indications for PrEP use by MSM

  • Adult man
  • Without acute or established HIV infection
  • Any male sex partners in past 6 months
  • Not in a monogamous partnership with a recently tested, HIV-negative man AND at least one of the following: any anal sex without condoms (receptive or insertive) in past 6 months, any STI diagnosed or reported in past 6 months, is in an ongoing sexual relationship with an HIV-positive male partner

Recommended indications for PrEP use by heterosexually active men and women

  • Adult person
  • Without acute or established HIV infection
  • Any sex with opposite sex partners in past 6 months
  • Not in a monogamous partnership with a recently tested HIV-negative partner AND at least one of the following: is a man who has sex with both women and men (behaviorally bisexual); infrequently uses condoms during sex with 1 or more partners of unknown HIV, status who are known to be at substantial risk of HIV infection; is in an ongoing sexual relationship with an HIV-positive partner

Recommended indications for PrEP use by injection drug users

  • Adult person
  • Without acute or established HIV infection
  • Any injection of drugs not prescribed by a clinician in past 6 months AND at least one of the following: any sharing of injection or drug preparation equipment in past 6 months; been in a methadone, buprenorphine or suboxone treatment program in past 6 months; risk of sexual acquisition

Resources for United States

  • Visit PrEPcost.org to help find the best health insurance options and coverage for patients interested in PrEP. The site is now available for 2020 open enrollment in all 50 states and the District of Columbia.
  • United States Local Programs – Use PrEPlocator.org to find providers who prescribe PrEP across the US, powered by the US Centers for Disease Control and Prevention’s (CDC) National Prevention Information Network (NPIN). Go to pleasePrEPme.org for a compilation PrEP services by state, and other PrEP-related US data.
  • US Women & PrEP Working Group – This group represents organizations and individuals pushing for programming and access to PrEP for women.
  • Email to join the online PrEP Access Advocates list: avac@avac.org
  • A Framework for Scaling Up PrEP can help implementers, government and advocates begin planning for and implementing PrEP programs.
  • Click here for the latest information from the United States Department of Health & Human Services.